Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

[1]  John E. Mullinax,et al.  Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group , 2021, Annals of Surgical Oncology.

[2]  H. V. van Boven,et al.  Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial. , 2020, JAMA oncology.

[3]  L. Mariani,et al.  Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case‐series analysis within the Italian Rare Cancer Network , 2020, Cancer.

[4]  Gang Huang,et al.  Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study , 2020, Clinical Cancer Research.

[5]  Robin L. Jones,et al.  Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. , 2020, The Lancet. Oncology.

[6]  S. Steinberg,et al.  Selumetinib in Children with Inoperable Plexiform Neurofibromas. , 2020, The New England journal of medicine.

[7]  J. Blay,et al.  Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. , 2020, The Lancet. Oncology.

[8]  C. Antonescu,et al.  Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  C. Valverde,et al.  1624MO Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS) , 2020 .

[10]  E. Fadel,et al.  Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of CTNNB1 Mutational Status , 2020, Clinical Cancer Research.

[11]  L. Mariani,et al.  The activity of chemotherapy in inflammatory myofibroblastic tumour (IMT): a multicentre, European retrospective case series analysis. , 2020, The oncologist.

[12]  E. Schröck,et al.  Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes , 2020, European Journal of Human Genetics.

[13]  J. Blay,et al.  Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Morgan,et al.  Effect of bilateral salpingo-oophorectomy on the overall survival of premenopausal patients with stage I low-grade endometrial stromal sarcoma; a National Cancer Database analysis. , 2020, Gynecologic oncology.

[15]  J. Wunder,et al.  Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet , 2020, Cancer.

[16]  J. Blay,et al.  Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group , 2020, Cancer.

[17]  J. Blay,et al.  Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. , 2020, JAMA oncology.

[18]  S. Dry,et al.  A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma , 2020, Clinical Cancer Research.

[19]  Robin L. Jones,et al.  The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. , 2020, European journal of cancer.

[20]  J. Blay,et al.  A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib. , 2020, European journal of cancer.

[21]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[22]  J. Wunder,et al.  Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors , 2019, EClinicalMedicine.

[23]  J. Desai,et al.  Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor , 2019, Scientific Reports.

[24]  David M. Thomas,et al.  Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial , 2019, The Lancet.

[25]  J. Castle,et al.  Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution , 2019, Journal of Immunotherapy for Cancer.

[26]  J. Blay,et al.  Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[27]  Robin L. Jones,et al.  Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas) , 2019, Clinical Cancer Research.

[28]  S. Litière,et al.  The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. , 2019, European journal of cancer.

[29]  Narasimhan P. Agaram,et al.  Sorafenib for Advanced and Refractory Desmoid Tumors , 2018, The New England journal of medicine.

[30]  J. Wunder,et al.  Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. , 2018, European journal of cancer.

[31]  K. S. Hall,et al.  Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series , 2018, JAMA oncology.

[32]  J. Blay,et al.  Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. , 2018, The Lancet. Respiratory medicine.

[33]  J. Blay,et al.  Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.

[34]  Peter Wust,et al.  Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial , 2018, JAMA oncology.

[35]  P. Casali,et al.  Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard? , 2018, Annals of Surgical Oncology.

[36]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[37]  B. Dickson,et al.  Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Blay,et al.  Improved survival using specialized multidisciplinary board in sarcoma patients. , 2017 .

[39]  D. Jamieson,et al.  Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial , 2017 .

[40]  J Bogaerts,et al.  ESMO-Magnitude of Clinical Benefit Scale version 1.1 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Robin L. Jones,et al.  Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Eva Ardanaz,et al.  Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. , 2017, The Lancet. Oncology.

[43]  M. Nucci,et al.  YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. , 2017, Gynecologic oncology.

[44]  P. Rutkowski,et al.  Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[45]  G. Rauch,et al.  Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). , 2017, European journal of cancer.

[46]  Robin L. Jones,et al.  Pazopanib, a promising option for the treatment of aggressive fibromatosis , 2017, Anti-cancer drugs.

[47]  L. Mariani,et al.  Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis , 2017, Cancer journal.

[48]  S. Bonvalot,et al.  Essential Requirements for Quality Cancer Care : Soft Tissue arcoma in Adults and Bone Sarcoma . A critical review , 2017 .

[49]  J. Blay,et al.  Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. , 2016, The Lancet Oncology.

[50]  Robin L. Jones,et al.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Llombart‐Bosch,et al.  Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[53]  U. Mansmann,et al.  Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection: A Subgroup Analysis of a Randomized Phase-III Multicenter Study , 2014, Annals of surgery.

[54]  S. Steinberg,et al.  Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial , 2014, Annals of Surgical Oncology.

[55]  P. Dileo,et al.  What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients , 2014, British Journal of Cancer.

[56]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[57]  P. Schwartz,et al.  Hormonal Therapy for Aggressive Angiomyxoma: A Case Report and Proposed Management Algorithm , 2014, Journal of lower genital tract disease.

[58]  C. Nezhat,et al.  Evaluating the risks of electric uterine morcellation. , 2014, JAMA.

[59]  Robin L. Jones,et al.  Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma , 2013, Sarcoma.

[60]  C. Morosi,et al.  Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics , 2013, Clinical Cancer Research.

[61]  J. Blay,et al.  Sorafenib in patients with progressive epithelioid hemangioendothelioma , 2013, Cancer.

[62]  David W. Henry,et al.  Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study , 2013, Pediatric blood & cancer.

[63]  Luigi Mariani,et al.  Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Wathen,et al.  Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma , 2013, Cancer.

[65]  A. D. Dei Tos,et al.  Sunitinib malate in solitary fibrous tumor (SFT). , 2012 .

[66]  J. Verweij,et al.  Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. , 2012, The Lancet. Oncology.

[67]  J. Coindre,et al.  Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  R. Zlotecki,et al.  The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity , 2012, Cancer.

[69]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[70]  C. Raut,et al.  Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTC–STBSG , 2012, Annals of Surgical Oncology.

[71]  L. Mariani,et al.  Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  A. D. Dei Tos,et al.  Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  Steven J. M. Jones,et al.  14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma , 2012, Proceedings of the National Academy of Sciences.

[74]  P. Ip,et al.  Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. , 2011, Best practice & research. Clinical obstetrics & gynaecology.

[75]  A. Lazar,et al.  Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor , 2011, Cancer.

[76]  A. Eggermont,et al.  Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Maurel,et al.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Robin L. Jones,et al.  Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. , 2009, European journal of cancer.

[79]  J. Roth,et al.  Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. , 2009, The Annals of thoracic surgery.

[80]  J. Blay,et al.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  M. Franchi,et al.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.

[82]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  A. Davis,et al.  Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial , 2002, The Lancet.

[84]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  E. Casper,et al.  Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  A. Cesne,et al.  High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  J. Crowley,et al.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.

[90]  J. Tepper,et al.  The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. , 1982, Annals of surgery.

[91]  J. Blay,et al.  Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[92]  L. Mariani,et al.  Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. , 2019, European journal of cancer.

[93]  F. Collin,et al.  Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. , 2016, European journal of cancer.

[94]  L. Mariani,et al.  Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. , 2016, The Lancet. Oncology.

[95]  T. Group,et al.  Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group , 2016, Annals of Surgical Oncology.